

INDEX

Note: Entries followed by “f” indicate figures; “t” tables.

- Abdominal hysterectomy, 267-268
Abetalipoproteinemia, 18t
Abscesses, 140-141, 200-202, 201f
ACG (American College of Gastroenterology), 67-68, 285
Acquired immunodeficiency syndrome. *See* AIDS (acquired immunodeficiency syndrome), diarrhea in.
ACS (American Cancer Society), 285
Acute diarrhea, 23-50. *See also* Diarrhea.
in AIDS, 23-50
anal intercourse and, 23-24
causes of, 23-25, 24t-25t
Clostridium difficile diarrhea, 40-44
dysentery, 25-34, 30t-32t
empiric treatments for, 28-29, 30t-32t
evaluations for, 29-49
foodborne outbreaks and, 29, 33t
lactose intolerance and, 38-40
malabsorption and, 38-40
nonspecific antidiarrheal therapies, 36-37
overviews and summaries of, 23-25
parasites and, 35t
pharmacological therapies for, 26-29, 30t-32t, 34-40
specific antidiarrheal therapies, 37-38
supportive treatments for, 34-36
traveler's diarrhea, 25-28
waterborne outbreaks and, 29
Acute diverticulitis, 133-144, 134t-135t. *See also* Diverticulitis.
Acute lower GI bleeding, 117-130
Acyclovir, 48t-49t
Addison's disease, 21t, 52t-53t
Adenomatous polyposis coli. *See* APC (adenomatous polyposis coli) genetic testing.
Adenomatous polyps, 233-240, 236f-237f, 237t, 269, 272-273
Adenovirus, 24t-25t
Adjuvant therapies, 24t-25t, 276-280, 278t
chemotherapy, 24t-25t, 277-280, 278t. *See also* Chemotherapy.
radiotherapy, 276-277
Adrenal insufficiency, 52t-53t
Aeromonas spp, 24t-25t
AGA (American Gastroenterological Association), 285-286
Aganglionic segment resection and bypass, 82
Agents, pharmacologic. *See* Pharmacologic agents and therapies.
Aging-related impacts, 65
Agranulocytosis, 170
AIDS (acquired immunodeficiency syndrome), diarrhea in, 23-50
AJCC (American Joint Commission on Cancer) Staging System, 269-271, 271t
Alarm symptoms, 72t, 98
Albendazole, 48t-49t
Alcohol consumption, 52t-53t, 64
Allergies, food, 23-24, 52t-53t
Aloe, 18t
Alopecia, 170
Alosetron, 105-107, 106t, 109-113
Aluminium-containing antacids, 15-17, 16t, 66, 66t
American Cancer Society. *See* ACS (American Cancer Society).
American College of Gastroenterology. *See* ACG (American College of Gastroenterology).
American Dietetic Association, 64
American Gastroenterological Association. *See* AGA (American Gastroenterological Association).
American Joint Commission on Cancer. *See* AJCC (American Joint Commission on Cancer) Staging System.
American Society for Gastrointestinal Endoscopy. *See* ASGE (American Society for Gastrointestinal Endoscopy).
American Society of Colon and Rectal Surgeons. *See* ASCRS (American Society of Colon and Rectal Surgeons).
Aminobenzoyl-beta-alanine. *See* 4-ABA (aminobenzoyl-beta-alanine).
Aminosalicylates, 58, 170-177, 175f
Amitiza, 73, 78-81. *See also* Lubiprostone.
Amoxicillin, 136-137
Amoxicillin/clavulanate, 136-137
Amphotericin, 48t-49t
Ampicillin, 138
Ampicillin/sulbactam, 138
Amsterdam criteria, 246
Amyloidosis, 52t-53t, 54-55, 66, 66t, 210
Anal fissures, 23-24, 63
Anal intercourse, 23-24
Anal myotomy, 82
Anastomosis, primary, 137, 140
Anatomic distribution, 203
Anatomic histology, 270f
Anemia, 170, 274-279, 274f, 279
Angiography, 126-128
Anorectal manometry with balloon expulsion, 70t
Antacids, 15-17, 16t, 66, 66t
Antibiotics, 24t-25t, 27-28, 57, 136-142, 180. *See also under individual drug names.*
Anticholinergic antispasmodics, 105-107, 106t
Anticonvulsants, 66, 66t
Antidepressants, low-dose vs tricyclic, 66, 66t, 73, 105-107, 106t
Antihypertensives, 66, 66t
Antioxidants, 252-254
Antiparkinsonian agents, 66, 66t
Antiretroviral therapy, highly active, 45-46, 48t-49t
Antispasmodics, 105-107, 106t
APC (adenomatous polyposis coli) genetic testing, 267-268
Aphthous ulcers, 201-202
Appendicitis, 132-133, 133t, 203-206
Asacol, 174t. *See also* Mesalamine.
Ascending colon polyps, 235, 236f
ASCRS (American Society of Colon and Rectal Surgeons), 286
ASGE (American Society for Gastrointestinal Endoscopy), 286
Aspirin, 252-253, 252t-253t
Associations, societies, and organizations, 285-291
Aster-Coller modification, 269-270, 271t
Atropine, 107
Augmentin, 136. *See also* Amoxicillin/clavulanate.

- Autonomic neuropathy, 57
 Azathioprine, 58, 210
 Azithromycin, 28, 30t-32t, 48t-49t
 Azithromycin/ethambutol, 48t-49t
 Azulfidine EN, 170-177, 174t. *See also* Sulfasalazine.
- Bacillus cereus*, 24t-25t
 Bacitracin, 44t
 Bacterial infections, 24t-25t
 Bacterial overgrowth, 52t-53t
Bacteroides spp and *Bacteroides fragilis*, 138
 Bactrim, 136. *See also* TMP/SMX (trimethoprim/sulfamethoxazole).
 Balsalazide, 58, 171-176, 174t
 Barium enemas, 121-122, 134t-135t, 136, 139-140. *See also* Enemas.
 Basic concepts. *See* Fundamental concepts; Overviews and summaries.
 Belladonna alkaloids, 105-107, 106t
 Benign colorectal stricture, 66, 66t
 Bentriomide tests, 61
 Bentlyl, 107. *See also* Dicyclomine.
 Betacarotene, 250t-251t, 251-254
 Bevacizumab, 277
 Bilateral salpingo-oophorectomy, 267-268
 Biology and epidemiology, xii-xiii, 233-284. *See also* Epidemiology.
 Biopsies, 242
 Bisacodyl, 18t, 74t
 Bismuth subsalicylate, 27-28
 Bladder resections, 140
Blastocystis carinii, 26t-27t
 Bowel disease (diagnosis and management) concepts. *See also under individual topics.*
 acute lower GI bleeding, 117-130
 clinical trials and research studies. *See* Clinical trials and research studies.
 constipation, 63-84
 CRC, 233-284
 epidemiology and biology of, 233-256
 management of, 269-284
 screening techniques for, 257-268
 diarrhea, 15-62
 acute and in AIDS, 23-50
 chronic, 51-62
 fundamentals of, 15-22
 diverticulitis, 131-144
 diverticulosis, 117-130
 educational materials and resource information, 285-291
 fundamentals, xii-xiii
 IBD, 145-232
 Crohn's disease, 199-232
 fundamentals of, 145-154
 UC, 155-198
 IBS, 85-116
 diagnosis of, 91-98
 fundamentals of, 85-90
 management of, 99-116
 overviews and summaries. *See* Overviews and summaries.
 pharmacologic agents and therapies. *See* Pharmacologic agents and therapies.
 Bowel movement urges, delay of, 65
- Brainerd diarrhea, 52t-53t
 Budesonide, 58
 Bulk-forming laxatives, 73-81, 74t, 77f-78f, 80f. *See also* Laxatives.
 Bullous edema, 140
- Cachexia, 57
 Caffeine-containing liquids, consumption of, 64
 Calcium, 15-17, 16t, 66, 66t, 74t, 105-107, 106t, 249-250, 253t
 antacids containing, 15-17, 16t, 66, 66t
 channel blockers, 66, 66t
 polycarophil, 74t, 105-107, 106t
 supplements, 249-250, 253t
Campylobacter spp and *Campylobacter jejuni*, 21-32, 21t, 24t-27t, 30t-32t, 211
 Canasa suppositories, 174t. *See also* Mesalamine.
 Cancer, colorectal. *See* CRC (colorectal cancer).
 Cancer Information Service. *See* CIS (Cancer Information Service).
 Cancer surveillance recommendations, 192t, 193-197, 194f-195f
 CancerNet, 286-287
Candida albicans, 24t-27t
 Capecitabine, 278t
 Carbohydrate malabsorption, 15-17, 16t
 Carcinogen-blocking agents, 249-250
 Carcinoid syndrome, 20t-21t
 Cascara, 18t, 58-59
 CBCs (complete blood counts), 54-55, 72, 133
 CCFA (Crohn's and Colitis Foundation of America), 287
 CCFC (Crohn's and Colitis Foundation of Canada), 287-288
 Cecum polyps, 235, 236f
 Celecoxib, 253-254, 253t
 Celiac disease, 21t, 54-55
 Chemotherapy, 24t-25t, 249-253, 277-280, 278t
 adjuvant, 24t-25t, 277-280, 278t
 chemopreventive agents, 249-253
Chlamydia trachomatis, 23-27, 26t-27t
 Chlordiazepoxide/clindinium bromide, 105-107, 106t
 Cholecystectomy, 18t, 52t-53t
 Cholestyramine, 44t, 105-107, 106t, 109
 Chronic bacterial/mycobacterial infections, 52t-53t
 Chronic Constipation Task Force, ACG (American College of Gastroenterology), 67-68
 Chronic diarrhea, 51-62. *See also* Diarrhea.
 causes of, 52t-53t
 collagenous colitis, 56-58, 58f
 diabetic diarrhea, 56-57
 dumping syndrome, 55-56
 factitious diarrhea, 58-59
 IBD and, 51-53, 52t-53t. *See also* IBD (inflammatory bowel disease).
 IBS and, 51-53, 52t-53t. *See also* IBS (irritable bowel syndrome).
 in ICUs, 59-60
 ileostomy diarrhea, 56-57
 initial evaluations of, 53-55
 lymphocytic colitis, 56-58, 58f
 malabsorption syndromes and, 51-53, 52t-53t
 microscopic colitis, 56-58
 overviews and summaries of, xi-xiii, 51-53
 parasitic infections and, 51-53

- Chronic diarrhea (*continued*)
 pharmacologic therapies for, 51-62
 of unknown origin, 60-61
- Chronic idiopathic (functional) constipation, 67-70, 69t-70t, 75-81. *See also* Constipation.
 constipation-predominant IBS, 69
 definition of, 68
 diagnostic tests for, 70t
 vs pelvic floor dysfunction, 66, 67t, 68-69
 pharmacologic therapies for, 75-81
 ROME III criteria for, 67-69, 69t
 vs slow-transit, 66, 67t, 68-69
- Chronic idiopathic intestinal pseudo-obstruction, 66, 66t
- Cilastatin. *See* Imipenem/cilastatin.
- Cipro, 136. *See also* Ciprofloxacin.
- Ciprofloxacin, 27-28, 30t-32t, 48t-49t, 136-137
- CIS (Cancer Information Service), 289
- Clarithromycin, 48t-49t
- Clavulanate. *See* Amoxicillin/clavulanate.
- Clindinium bromide. *See* Clordiazepoxide/clindinium bromide.
- Clinical toxicity, 137
- Clinical trials and research studies. *See also under individual topics.*
 for constipation, 67-70, 75-81
 for CRC, 233-242, 249-253, 250t-251t, 257-259, 258t-259t, 278t
 Danish Trial, 258, 259t
 for diarrhea, 17, 27-49, 55
 for diverticulitis, 136-144
 for IBS, 99-102, 105-116
 Minnesota Trial, 257-259, 258t-259t
 MOSAIC, 278t
 National Polyp Study, 233-240
 Nottingham Study, 258, 259t
 NSABP C07, 278t
 PETACC-3, 278t
 X-ACT, 278t
- Clonidine, 57
- Clostridium difficile* diarrhea, 40-44
- Clostridium* spp, 24t-27t, 59-60, 211, 215-216
Clostridium difficile, 24t-27t, 59-60, 211, 215-216
Clostridium perfringens, 24t-25t
- Clubbing, 208
- CMV (cytomegalovirus), 26t-27t
- Cobblestone appearance, 202
- Coccidioides*, 26t-27t
- Codeine, 56-57
- Coexisting diseases and conditions, 66, 67t
- Colazal, 171, 174t. *See also* Balsalazide.
- Colchicine, 24t-25t
- Colectomy, 58, 81-82, 274-276, 275f
 with *en bloc* removal, 274
 hemicolectomy, 274-276, 275f
 laparoscopic-assisted, 276
 subtotal, 81-82
 transverse, 274-276
- Colitis, 56-58, 58f, 155-198, 268
 collagenous, 56-58, 58f
 lymphocytic, 56-58, 58f
- Colitis (*continued*)
 microscopic, 56-58
 pancolitis, 268
 ulcerative, 155-198. *See also* UC (ulcerative colitis).
- Collagen vascular diseases, 18t
- Collagenous colitis, 52t-53t, 56-58, 58f
- Coloanal reanastomoses, 276
- Colocutaneous fistulas, 140
- Colon Cancer Information Center and Library, 287
- Colon transit studies, 70t
- Colonic fistulas, 230
- Colonic inertia, 68
- Colonic spasms, 138
- Colonoscopy, 54-55, 72, 122, 128, 260t-261t, 262
- Colorectal cancer. *See* CRC (colorectal cancer).
- Colorectal Crohn's disease, 227-229, 229f. *See also* Crohn's disease.
- Colostomy, emergency, 142
- Colovesical fistulas, 139-140
- CoLYTE, 16t, 128
- Complete spontaneous bowel movements. *See* CSBMs (complete spontaneous bowel movements).
- Congenital fructose malabsorption, 15-17, 16t
- Congenital glucose-galactose malabsorption, 15-17, 16t
- Constipation, 63-84
 causes of, 64-67, 66t-67t
 bowel movement urges, delay of, 65
 coexisting diseases and conditions, 66, 67t
 CRC and, 66, 67t
 daily routine changes, 65
 dietary factors, 64
 IBS and, 66, 67t, 68-69
 laxatives, abuse of, 65
 medications, 66, 66t
 physical activity levels, 64-65
 primary diseases and disorders, colon and rectum, 66, 67t
- chronic idiopathic (functional), 67-70, 69t-70t, 75-81
 constipation-predominant IBS, 69
 definition of, 68
 diagnostic tests for, 70t
 vs pelvic floor dysfunction, 66, 67t, 68-69
 pharmacologic therapies for, 75-81
 ROME III criteria for, 67-69, 69t
 vs slow-transit, 66, 67t, 68-69
- clinical trials and research studies for, 67-70, 75-81
- evaluation of, 70-72
 alarm symptoms, 72t
 anorectal manometry with balloon expulsion, 70t
 colon transit studies, 70t
 defecography, 70t
 diagnostic tests, 69t-70t, 70t, 71-72, 72t
 fluoroscopy, 70t
 histories, 71
 physical examinations, 71
 management of, 72-82, 74t, 77f-78f, 80f
 pharmacologic therapies, 72-81, 74t, 77f-78f, 80f
 surgical interventions for, 81-82

- Constipation (*continued*)
 overviews and summaries of, xii-xiii, 63, 82
 surgical interventions for, 81-82
 treatment of, 72-81, 72t-73t, 77f-78f, 80f
- Constipation-predominant IBS, 107-108. *See also* IBS (irritable bowel syndrome).
- Contrast enemas, 134t-135t, 136, 139-140
- Cortenema, 179-180
- Corticosteroids, 56-57, 178-180, 217
- Cortifoam, 179-180
- COX (cyclooxygenase)-2 inhibitors, 252-253, 253t
- CRC (colorectal cancer), 233-284
 clinical trials and research studies for, 233-242, 249-253, 250t-251t, 257-259, 258t-259t, 278t
 Danish Trial, 258, 259t
 Minnesota Trial, 257-259, 258t-259t
 MOSAIC, 278t
 National Polyp Study, 233-240
 Nottingham Study, 258, 259t
 NSABP C07, 278t
 PETACC-3, 278t
 X-ACT, 278t
- constipation and, 66, 66t, 240-241
- epidemiology and biology of, 233-256
 clinical features, 233-234, 234f-235f
 genetic models, 244
 incidence and prevalence, 233, 234f-235f
 mortality rates, 234f
 overviews and summaries of, 233
 pathogenesis, 240-244, 241f, 243f-244f
 polyps, 234-240, 236f-240f
 primary prevention, 248t, 249-253, 250t-252t
 risk factors, 245-249, 245f, 247f, 248t
- fundamental concepts for, xii-xiii
- management of, 269-284
 anatomic histology and, 270f
 chemotherapy, adjuvant, 277-282, 278t
 clinical symptoms, 270-272, 274t
 guidelines, colon cancer-specific, 277-282
 guidelines, rectal cancer-specific, 282-284
 overviews and summaries of, 269
 radiotherapy, 276-277
 staging criteria, 269-270, 270f, 271t, 272f-273f
 surgical interventions, 273-276, 275f
 survival rates, 272f-273f
- screening techniques for, 257-268
 algorithm for, 264f-265f
 APC genetic testing, 267-268
 colonoscopy, 260t-261t, 262
 CT colonography, 260t-261t, 262-263
 DCBEs, 260t-261t, 262
 flexible sigmoidoscopy, 260t-261t, 262
 FOBTs, 257-261, 258t-261t
 normal-risk individuals, 257-263, 258t-261t
 overviews and summaries of, 257-258
 positive family histories, 263-268, 264f-265f
- Crohn's and Colitis Foundation of America. *See* CCFA (Crohn's and Colitis Foundation of America).
- Crohn's and Colitis Foundation of Canada. *See* CCFC (Crohn's and Colitis Foundation of Canada).
- Crohn's disease, 199-232. *See also* IBD (inflammatory bowel disease).
 anatomic distribution and, 203
 vs appendicitis, 203-206
 Crohn's Disease Activity Index, 215-216
 diagnosis of, 211-217, 212t-213t, 214f-215f
 epidemiology of, 199-200
 extraintestinal manifestations of, 208-210, 209f
 miscellaneous, 210
 musculoskeletal, 208-210, 209f
 skin, 208
- fistulas and, 139-140, 230
 ileal (colorectal) Crohn's disease, 227-229, 229f
 management of, 217-226, 220f-221f
 acute flares, 219-226
 maintenance therapy, 226
 mild-to-moderate disease, 219-222
 moderate-to-severe disease, 222-223
 overviews and summaries of, 199-200
 pathology of, 200-202, 201f-202f
 severe-to-fulminant disease, 225-226
 signs and symptoms of, 203-208, 204t-205t
 clinical features, 204t-205t
 disease patterns, 206-208
 fibrotic/obstructive disease, 206
 fistulous/penetrating disease, 207-208
 surgical interventions for, 226-230, 229f
 indications for, 226-227
 procedures, 227-230, 229f
 vs UC, 199-200, 203, 208. *See also* UC (ulcerative colitis).
- Crohn's Disease Activity Index, 215-216
- Crypt abscesses, 200-202, 201f
- Cryptaz, 48t-49t. *See also* Nitazoxanide.
- Cryptitis, 200-202, 201f
- Cryptococcus*, 26t-27t
- Cryptosporidium*, 21t, 24t-27t
- CSBMs (complete spontaneous bowel movements), 76-80
- CT colonography (virtual colonoscopy), 260t-261t, 262-263
- CT (computed tomography), 54-55
- Curcumin, 252-254
- Cutaneous erythema, 21t
- Cyclooxygenase-2 inhibitors. *See* COX (cyclooxygenase)-2 inhibitors.
- Cyclospora cayentanensis*, 24t-27t
- Cyclosporine, 182-183
- Cytomegalovirus. *See* CMV (cytomegalovirus).
- DAG (diacylglycerol), 24l
- Daily routine changes, 65
- Danish Trial, 258, 259t
- DCBEs (double-contrast barium enemas), 260t-261t, 262
- DDNC (Digestive Disease National Coalition), 288
- Defecography, 70t
- Dehydration, 17, 64
- Deionated tincture, opium, 47

- Delay, bowel movement urges, 65
- Demerol, 138. *See also* Meperidine.
- Dentures, ill-fitting, 64
- Dermatitis herpetiformis, 21t
- Descending colon polyps, 235, 236f
- DEXA (dual energy x-ray absorptiometry), 178-180, 208-210, 209f
- DFMO (difluoromethylornithine), 252-253
- Diabetes mellitus, 19t, 20t-21t, 52t-53t, 66, 66t, 74-75
- Diabetic autonomic neuropathy, 66, 66t
- Diabetic diarrhea, 56-57
- Diacylglycerol. *See* DAG (diacylglycerol).
- Diagnosis and management concepts (bowel diseases). *See also under individual topics.*
- acute lower GI bleeding, 117-130
 - clinical trials and research studies. *See* Clinical trials and research studies.
 - constipation, 63-84
 - CRC, 233-284
 - epidemiology and biology of, 233-256
 - management of, 269-284
 - screening techniques for, 257-268
 - diarrhea, 15-62
 - acute and in AIDS, 23-50
 - chronic, 51-62
 - fundamentals of, 15-22
 - diverticulitis, 131-144
 - diverticulosis, 117-130
 - educational materials and resource information, 285-291
 - fundamentals, xii-xiii
 - IBD, 145-232
 - Crohn's disease, 199-232
 - fundamentals of, 145-154
 - UC, 155-198
 - IBS, 85-116
 - diagnosis of, 91-98
 - fundamentals, 85-90
 - fundamentals of, 85-90
 - management of, 99-116
 - overviews and summaries. *See* Overviews and summaries.
 - pharmacologic agents therapies. *See* Pharmacologic agents and therapies.
- Diarrhea, 15-62. *See also under individual topics.*
- acute, 23-50
 - in AIDS, 23-50
 - anal intercourse and, 23-24
 - causes of, 23-25, 24t-25t
 - Clostridium difficile* diarrhea, 40-44
 - dysentery, 25-34, 30t-32t
 - empiric treatments for, 28-29, 30t-32t
 - evaluations for, 29-49
 - foodborne outbreaks and, 29, 33t
 - lactose intolerance and, 38-40
 - malabsorption and, 38-40
 - nonspecific antidiarrheal therapies, 36-37
 - overviews and summaries of, 23-25
 - parasites and, 35t
 - pharmacological therapies for, 26-29, 30t-32t, 34-40
 - specific antidiarrheal therapies, 37-38
 - Diarrhea, acute (*continued*)
 - supportive treatments for, 34-36
 - traveler's diarrhea, 25-28
 - waterborne outbreaks and, 29
 - chronic, 51-62
 - causes of, 52t-53t
 - collagenous colitis, 56-58, 58f
 - diabetic diarrhea, 56-57
 - dumping syndrome, 55-56
 - factitious diarrhea, 58-59
 - IBD and, 51-53, 52t-53t. *See also* IBD (inflammatory bowel disease).
 - IBS and, 51-53, 52t-53t. *See also* IBS (irritable bowel syndrome).
 - in ICUs, 59-60
 - ileostomy diarrhea, 56-57
 - initial evaluations of, 53-55
 - lymphocytic colitis, 56-58, 58f
 - malabsorption syndromes and, 51-53, 52t-53t
 - microscopic colitis, 56-58
 - overviews and summaries of, 51-53
 - parasitic infections and, 51-53
 - pharmacologic therapies for, 51-62
 - of unknown origin, 60-61
 - clinical trials and research studies for, 17, 27-49, 55
 - fundamentals of, xi-xiii, 15-22
 - approaches, 17-21
 - associated conditions, 18t-19t
 - causes of, 15-17, 16t
 - definitions, 15
 - dysmotility, 19t
 - exudative diarrhea, 19t
 - histories, 17
 - osmotic diarrhea, 15-17, 16t
 - overviews and summaries of, 15
 - physical examinations, 17
 - risk factors, 15-16
 - secretory diarrhea, 18t-19t
 - world travel and, 15-17
 - Diarrhea-predominant IBS, 108-115. *See also* IBS (irritable bowel syndrome).
 - Dicyclomine, 105-107, 106t
 - Dietary factors, 64
 - Dietary fiber, 118
 - Dietary modifications, 102-104
 - Difluoromethylornithine. *See* DFMO (difluoromethylornithine).
 - Digestive Disease National Coalition. *See* DDNC (Digestive Disease National Coalition).
 - Digoxin, 24t-25t
 - Dipentum, 171, 174t. *See also* Olsalazine.
 - Diphenoxylate-atropine, 47, 56-57, 109
 - Disaccharidase deficiencies, 15-17, 16t
 - Diuretics, 24t-25t, 66, 66t
 - Diverticular bleeding, 122-128, 125f
 - Diverticulitis, 131-144
 - acute, 133-144, 134t-135t
 - vs appendicitis, 132-133, 133t
 - clinical trials and research studies for, 136-144

- Diverticulitis (*continued*)
- complications of, 139-142
 - abscesses, 140-141
 - fistulas, 139-140
 - peritonitis, generalized, 131-132, 141-142
 - vs CRC, 132
 - diagnostic studies for, 133-136, 134t-135t
 - CBCs, 133
 - colonoscopy, 136, 139-140
 - contrast enemas, 134t-135t, 136, 139-140
 - CT scans, 133, 134t-135t, 138-142
 - obstruction series, 133-134
 - sigmoidoscopy, 136
 - ultrasound, 134t-135t, 141
 - differential diagnosis of, 132
 - vs diverticulosis, 130. *See also* Diverticulosis.
 - epidemiology of, 131
 - vs IBD, 132
 - vs IBS, 132
 - life-threatening, 132
 - management of, 136-138
 - overviews and summaries of, xii-xiii, 131
 - pathogenesis of, 131-132
 - pharmacologic therapies for, 136-144
 - right colonic, 132-133, 133t, 136-138
 - signs of, 132
 - surgical interventions for, 142-144
 - indications for, 142-143
 - one-step procedure, 141, 143
 - options for, 143-144
 - two-step Hartmann's procedures, 144
 - symptoms of, 132
- Diverticulosis, 117-130
- clinical manifestations of, 121
 - clinical patterns of, 118-120
 - diagnosis of, 121-122
 - diagnostic studies for, 124-128
 - anatomy and bloody supply and, 127f
 - angiography, 126-128
 - barium enemas, 121-122
 - colonoscopy, 122, 128
 - nuclear scanning, 124-126
 - proctoscopy, 124, 124f
 - sigmoidoscopy, 122
 - dietary fiber and, 118
 - epidemiology of, 117
 - vs IBS, 122
 - lower GI (diverticular) bleeding, acute, 122-128, 125f
 - management of, 122-144
 - overviews and summaries of, xii-xiii, 117-118
 - painful diverticular disease, 122
 - pathogenesis of, 117-118, 119f-120f
- Dizziness, orthostatic, 55-56
- Docusate sodium, 18t
- Donnatal and Donnatal Extentabs, 107
- Double-balloon enteroscopy, 215
- Double-contrast barium enemas. *See* DCBEs (double-contrast barium enemas).
- Drug- and medication-related data. *See* Pharmacologic agents and therapies.
- Dual energy x-ray absorptiometry. *See* DEXA (dual energy x-ray absorptiometry).
- Duke's classification, 259t-261t, 269-270, 271t
- Dumping syndrome, 55-56
- Dysentery, 25-34, 29-34, 30t-32t
- Dysmotility, 19t
- Dyspepsia, 93
- Dysplasia, high-grade, 234-239, 238f
- Dyssynergic defecation, 69
- Dysuria, 139
- Edema, bullous, 140
- Educational materials and resource information, 285-291.
- EHEC (enterohemorrhagic *Escherichia coli*), 30t-32t
- EIEC (enteroinvasive *Escherichia coli*), 30t-32t
- Electrolyte imbalances, 74-80
- Emergency colostomy, 142
- Emulsions, lipid, 210
- En bloc* removal, regional lymph nodes, 274
- Endocrine and metabolic disorders, 66, 66t
- Enemas, 54-55, 73, 121-122, 134t-135t, 136, 139-140, 260t-261t, 261t, 262
 - barium enemas, 121-122
 - contrast, 134t-135t, 136, 139-140
 - DCBEs, 260t-261t, 262
 - Gastrografin, 134t-135t, 136, 139-140
- Entamoeba histolytica*, 23-24, 24t-27t
- Enteral nutrition, 151-153
- Enteritis, radiation, 52t-53t
- Enteroclysis, 54-55
- Enterointestinal fistulas, 230
- Enterohemorrhagic *Escherichia coli*, 30t-32t
- Enteroinvasive *Escherichia coli*, 30t-32t
- Enteropathogenic *Escherichia coli*, 30t-32t
- Enterotoxigenic *Escherichia coli*, 30t-32t
- EPEC (enteropathogenic *Escherichia coli*), 30t-32t
- Epidemiology, 117, 131, 155, 199-200, 233-256
 - of CRC, 233-256
 - of Crohn's disease, 199-200
 - of diverticulitis, 131
 - of diverticulosis, 117
 - of UC, 155
- Erythema nodosum, 208
- Erythrocyte sedimentation rates, 54-55
- Escherichia coli*, 24t-27t, 30t-32t, 138, 211
- Esomeprazole, 28
- ETEC (enterotoxigenic *Escherichia coli*), 30t-32t
- Ethambutol. *See* Azithromycin/ethambutol.
- Extraintestinal manifestations, 167-169, 168f, 208-210, 209f
- Extrinsic compression by tumor, 66, 66t
- Exudative diarrhea, 19t
- Factitious diarrhea, 58-59
- Famciclovir, 48t-49t
- Familial adenomatous polyposis. *See* FAP (familial adenomatous polyposis).
- Family histories, 263-268, 264f-265f

FAP (familial adenomatous polyposis), 245-249, 245f, 248t, 262, 266-268
 Fatty liver, 210
 Febrile dysentery, 30t-32t. *See also* Dysentery.
 Fecal impaction, 63
 Fecal occult blood tests. *See* FOBTs (fecal occult blood tests).
 Fecaloliths, 131-132, 141, 142
 Fecaluria, 132, 139
 Feculent peritonitis, 142
 Fiber supplements, 73-74
 Fibrosing alveolitis, 171
 Fibrostenotic/obstructive disease, 206
 Fistulas, 139-140, 230
 Fistulous/penetrating disease, 207-208
 Five-ASA (aminosalicylic acid), 56-57, 170-171
 Five-FU (5-fluorouracil), 24t-25t, 276-283, 278t
 Five-HT (hydroxytryptamine), 75-76
 Flexible sigmoidoscopy, 54-55, 260t-261t, 262
 FLOX (FU/LV), 277-284, 278t
 Fluconazole, 48t-49t
 Fluoroquinolones, 28, 30t-32t, 56-57
 Fluoroscopy, 70t
 Fluorouracil. *See* FU (fluorouracil).
 Flushing, 20t-21t, 55-56
 FOBTs (fecal occult blood tests), 257-261, 258t-261t
 FOLFOX (FU/oxaliplatin/LV), 277-284, 278t
 Folic acid supplements, 249-250
 Food allergies, 23-24, 52t-53t
 Food poisoning, 24t-25t
 Foodborne diarrhea outbreaks, 29, 33t
 Four-ABA (aminobenzoyl-beta-alanine), 171
 Free intraperitoneal/retroperitoneal air, 133-134
 Frequency, 132
 Fructose malabsorption, congenital, 15-17, 16t
 FU (fluorouracil), 276-283, 278t
 Fumagillin, 48t-49t
 Functional constipation, 67-70, 69t-70t, 75-81. *See also* Constipation.
 constipation-predominant IBS, 69
 definition of, 68
 diagnostic tests for, 70t
 vs pelvic floor dysfunction, 66, 67t, 68-69
 pharmacologic therapies for, 75-81
 ROME III diagnostic criteria for, 67-69, 69t
 vs slow-transit, 66, 67t, 68-69
 Fundamental concepts, xii-xiii. *See also* Overviews and summaries.
 for diarrhea, 15-22
 for IBD, 145-154
 for IBS, 85-90
 Fungi-induced diarrhea, 26t-27t
 Gallstones, 210
 Ganglioneuroma, 52t-53t
 Gardner's syndrome, 246
 Gastrectomy, 52t-53t
 Gastrografin enemas, 134t-135t, 136, 139-140
 Gastrointestinal lavage solutions, 16t
 Gastrointestinal Study Group modification. *See* GITSG (Gastrointestinal Study Group) modification.
 Gastrostomy, percutaneous, 281
 Generalized peritonitis, 131-132, 141-142
 Genetic factors, 156
 Genetic models, 244
 Gentamicin, 138
Giardia spp and Giardia lamblia, 21t, 24t-27t, 54-55
 GITSG (Gastrointestinal Study Group) modification, 272f-273f
 Glucagonoma syndrome, 19t, 21t
 Glucose-galactose malabsorption, congenital, 15-17, 16t
 GoLYTELY, 16t, 128
 Gonorrhea, 23-24
 Grafts, vascular, 30t-32t
 Guaiaac-based FOBTs (fecal occult blood tests), 257-261, 258t-261t
 Guarding, involuntary, 132
 HAART (highly active antiretroviral therapy), 45-46, 48t-49t
 HACA (human antichimeric antibodies), 185
 Hamartomas, 234-235
 Hartmann's procedure, two-step, 144
 Heart failure, 253
 Heavy metal poisoning, 52t-53t
 Hematochezia, 70t
 Hemicolectomy, 274-276
 Hemocult II and Hemocult II sensa, 257-261, 258t-261t
 Hemolytic anemia, 170
 Hemolytic-uremic syndrome, 30t-32t
 Hemorrhoids, 23-24, 63
 Hereditary nonpolyposis colon cancer. *See* HNPCC (hereditary nonpolyposis colon cancer).
 Herpes simplex, 23-24
 High-fiber diets, 136-138
 High-grade dysplasia, polyps, 234-239, 238f
 Highly active antiretroviral therapy. *See* HAART (highly active antiretroviral therapy).
 Hirschsprung's disease, 66, 66t, 69, 70t, 82
 Histology, anatomic, 270f
Histoplasma spp, 26t-27t
 Histories, 17, 71
 HNPCC (hereditary nonpolyposis colon cancer), 242, 245-249, 247f, 248t, 262, 266-268
 Human antichimeric antibodies. *See* HACA (human antichimeric antibodies).
 Hydrocortisone, 179-180
 Hydrogen breath testing, 60-61
 Hydroxytryptamine. *See* 5-HT (hydroxytryptamine).
 Hyoscyamine, 105-107, 106t
 Hypercalcemia, 66, 66t
 Hyperlipidemia, 210
 Hyperpigmentation, 58
 Hyperplastic polyps, 234-235
 Hyperthermia, 132
 Hyperthyroidism, 19t, 20t-21t, 52t-53t
 Hypochlorhydria, 28
 Hypoglycemia, 55-56
 Hypokalemia, 19t
 Hypoparathyroidism, 52t-53t
 Hypothyroidism, 66, 66t

- Hysterectomy, 139
- Hysterectomy, abdominal, 267-268
- IBD (inflammatory bowel disease), 145-232. *See also under individual topics.*
- clinical trials and research studies for, 171-193, 215
 - Crohn's disease, 199-232
 - anatomic distribution and, 203
 - vs appendicitis, 203-206
 - Crohn's Disease Activity Index, 215-216
 - diagnosis of, 211-217, 212t-213t, 214f-215f
 - epidemiology of, 199-200
 - extraintestinal manifestations of, 208-210, 209f
 - fistulas and, 139-140, 230
 - ileal Crohn's disease, 227-229, 229f
 - management of, 217-226, 220f-221f
 - mild-to-moderate disease, 219-222
 - moderate-to-severe disease, 222-223
 - overviews and summaries of, 199-200
 - pathology of, 200-202, 201f-202f
 - severe-to-fulminant disease, 225-226
 - signs and symptoms of, 203-208, 204t-205t
 - surgical interventions for, 226-230, 229f
 - fundamentals of, xi-xiii, xii-xiii, 145-154
 - clinical features, 146t-148t
 - etiology, 145-149
 - management, 149-150
 - nutrition factors, 151-153, 153t
 - overviews and summaries of, 145
 - putative risk factors, 149t
 - UC, 155-198
 - cancer surveillance recommendations for, 192t, 193-197, 194f-195f
 - clinical severity of, 185-190
 - diagnosis of, 160-166, 162t-163t, 163f, 166f
 - epidemiology of, 155
 - etiology of, 156
 - extraintestinal manifestations of, 167-169, 168f
 - genetic factors for, 156
 - management of, 170-193
 - overviews and summaries of, 155
 - pathology of, 156-159, 158f-159f
 - pharmacologic therapies, 170-193, 172f-173f, 174t, 175f, 192t
 - physical findings for, 160
 - surgical interventions for, 190-193
 - symptoms of, 160
- IBD News Digest, 288
- IBS (irritable bowel syndrome), 85-116. *See also under individual topics.*
- clinical trials and research studies for, 99-102, 105-116
 - constipation and, 66, 66t
 - diagnosis of, 91-98
 - basic, 96f
 - clinical features, 94-95
 - overviews and summaries of, 91
 - physical examinations, 95-98
 - ROME III criteria for, 91-94, 92t
 - sequential strategies for, 91
 - fundamentals of, xii-xiii, 85-90
 - definitions, 85
 - IBS (irritable bowel syndrome), fundamentals of (*continued*)
 - epidemiology, 85-86
 - overviews and summaries of, 85
 - pathophysiology, 86-88
 - psychological stressor conceptual model, 87-88, 89f
 - symptoms, 85-86
 - management of, 99-116
 - constipation-predominant IBS, 107-108
 - diarrhea-predominant IBS, 108-115
 - dietary modifications, 102-104
 - initial treatments, 100t-101t
 - overviews and summaries of, 99-102, 115
 - pharmacologic therapies, 105-116
 - psychological therapy, 104-105
 - symptom severity classification, 103t
 - ICUs (intensive care units), chronic diarrhea in, 59-60
 - Idiopathic bile acid absorption, 52t-53t, 60-61
 - Idiopathic chronic diarrhea, 52t-53t
 - IFFGD (International Foundation for Functional Gastrointestinal Disorders), 288-289
 - Ileal Crohn's disease, 227-229, 229f. *See also Crohn's disease.*
 - Ileorectal anastomosis, 81-82, 267-268
 - Ileostomy diarrhea, 56-57
 - Imbalances, electrolyte, 74-80
 - Imipenem/cilastatin, 138
 - Immunomodulators, 180-185
 - Immunosuppressive agents, 58
 - Imodium, 28, 47, 108-109. *See also Loperamide.*
 - Imuran, 180-182, 182f. *See also Azathioprine.*
 - In situ* carcinomas, 269
 - Indole-3-carbinol, 249-250
 - Inflammatory bowel disease. *See IBD (inflammatory bowel disease).*
 - Inflammatory diarrhea, 19t
 - Infliximab, 184-185
 - Inspissated fecal matter, 131-132
 - Intercourse, anal, 23-24
 - Intercurrent infections, 215-216
 - International Foundation for Functional Gastrointestinal Disorders. *See IFFGD (International Foundation for Functional Gastrointestinal Disorders).*
 - Internet resources, 285-291
 - Intestinal obstructions, 66, 66t
 - Intestinal resections, 52t-53t
 - Intraperitoneal air, 133-134
 - Intravenous hydration. *See IV (intravenous) hydration.*
 - Introductory concepts. *See Fundamental concepts; Overviews and summaries.*
 - Involuntary guarding, 132
 - Irinotecan, 277
 - Iron supplements, 66, 66t
 - Irritable bowel syndrome. *See IBS (irritable bowel syndrome).*
 - Ischemic bowel disease, 52t-53t
 - Isospora belli*, 26t-27t
 - IV (intravenous) hydration, 137-138

Jaundice, 132

Jejunioileal bypass, 18t

Jevity, 60
 Juvenile polyposis syndrome, 242

K-*ras* oncogene, 241-242
 Kaposi sarcoma, 26t-27t
 Kidney stones, oxalate, 210

Lactase deficiency, 15-17, 16t
 Lactose-free diets, 40t, 55
 Lactose intolerance, 38-40
 Lactulose, 74t, 105-107, 106t
 Lansoprazole, 28
 Laparoscopic-assisted colectomy, 276
 Laparoscopic resections, 137
 Latex particle agglutination immunoassays, 41-43
 Lavage solutions, 16t

Laxatives, 15-17, 16t, 24t-25t, 51-61, 71-81, 74t, 77f-78f, 80f
 abuse of, 51-61
 bulk-forming, 73-81, 74t, 77f-78f, 80f
 enemas as, 73
 osmolar, 73-81, 74t, 77f-78f, 80f
 OTC, 65, 73-75
 saline, 75
 stimulant, 18t, 73-81, 74t, 77f-78f, 80f

Lead pipe appearance, 202, 202f
Leishmania donovani, 26t-27t
 Leucovorin. *See* LV (leucovorin).
 Leukocytosis, 132-134, 137
 Levamisole, 277
 Levbid, 107
 Levofloxacin, 28, 30t-32t, 136-138
 Levsin SL, 107
 Lialda, 174t. *See also* Mesalamine.
 Librax, 107

Life-threatening diverticulitis, 132
 Lipid emulsions, 210
 Liquid diets, 136-138
 Lomotil, 47, 109. *See also* Diphenoxylate-atropine.
 Loperamide, 28, 47, 56-57, 105-109, 106t
 Lotronex, 109-113. *See also* Alosetron.
 Low-dose antidepressants, 73
 Low-fiber diets, 138
 Low residue diets, 136-138
 Lower GI bleeding, acute, 117-130
 Lubiprostone, 73, 78-82, 80f
 LV (leucovorin), 277-280, 278t
 Lymphadenopathy, 21t
 Lymphangiectasia, 18t
 Lymphocytic colitis, 52t-53t, 56-58, 58f
 Lymphoma, 26t-27t
 Lynch Syndrome Type I, 246

Macroperforations vs microperforations, 131-132
 Macrophages, 201-202
 Magnesium, 16t, 24t-25t, 74t, 105-107, 106t
 drugs containing, 24t-25t, 74t, 105-107, 106t
 induced diarrhea, 16t

Malabsorption and malabsorption syndromes, 38-40, 51-53, 52t-53t
 Malignant carcinoid syndrome, 19t
 Management and diagnosis concepts (bowel diseases). *See also under individual topics.*
 acute lower GI bleeding, 117-130
 clinical trials and research studies. *See* Clinical trials and research studies.
 constipation, 63-84
 CRC, 233-284
 epidemiology and biology of, 233-256
 management of, 269-284
 screening techniques for, 257-268
 diarrhea, 15-62
 acute and in AIDS, 23-50
 chronic, 51-62
 fundamentals of, 15-22
 diverticulitis, 131-144
 diverticulosis, 117-130
 educational materials and resource information, 285-291
 fundamentals, xii-xiii
 IBD, 145-232
 Crohn's disease, 199-232
 fundamentals of, 145-154
 UC, 155-198
 IBS, 85-116
 diagnosis of, 91-98
 fundamentals, 85-90
 fundamentals of, 85-90
 management of, 99-116
 overviews and summaries. *See* Overviews and summaries.
 pharmacologic agents and therapies. *See* Pharmacologic agents and therapies.
 Mannitol, 16t
 Manometry with balloon expulsion, 70t
 Mastocytosis, systemic, 21t, 52t-53t
 Measles virus associations, 200
 Medication- and drug-related data. *See* Pharmacologic agents and therapies.
 Megaloblastic anemia, 171
 Megarectum, 69
 Meperidine, 138
 Mercaptopurine. *See* 6-MP (mercaptopurine).
 Mesalamine, 58, 174t, 176-178, 210
 Metabolic and endocrine disorders, 66, 66t
 Methotrexate, 24t-25t, 58
 Methylcellulose, 74t, 105-107, 106t
 Metronidazole, 30t-32t, 44t, 56-57, 136-138
 MI (myocardial infarction), 253-254
 Microperforations vs macroperforations, 131-132
 Microscopic colitis, 56-58
 Microscopic diarrhea, 52t-53t
 Mild-to-moderate Crohn's disease, 219-222. *See also* Crohn's disease.
 Milk of Magnesia, 75
 Minnesota Trial, 257-259, 258t-259t
 Mixed connective tissue disease, 19t
 MMX technology, 176-177
 Moderate-to-severe Crohn's disease, 222-223. *See also* Crohn's disease.
 Morphine, 138
 MOSAIC (Multicenter International Study of Oxaliplatin/5FU/LC on the Adjuvant Treatment of Colon Cancer), 278t

- MS (multiple sclerosis), 66, 66t
Mucosal tags, 234-235
Muir-Torre syndrome, 248t
Multiple sclerosis. *See* MS (multiple sclerosis).
Mycobacterium spp, 26t-27t, 200, 211
Mycobacterium avium-intracellulare, 26t-27t, 211
Mycobacterium paratuberculosis, 200
Myocardial infarction. *See* MI (myocardial infarction).
Mycosis, 118
Myotomy, anal, 82
- Narcotics, 66, 66t
Nasogastric tubes, 137-138
National Cancer Institute. *See* NCI (National Cancer Institute).
National Digestive Diseases Information Center. *See* NDDIC (National Digestive Diseases Information Center).
National Institutes of Diabetes and Digestive and Kidney Diseases.
See NIDDK (National Institutes of Diabetes and Digestive and Kidney Diseases).
National Institutes of Health. *See* NIH (National Institutes of Health).
National Polyp Study, 233-240
Nausea, 133t
NCI (National Cancer Institute), 289-291
NDDIC (National Digestive Diseases Information Center), 290
Nephrotic syndrome, 210
Nephrotoxicity, 171
Neuroendocrine tumors, 52t-53t
Neurologic disorders, 66, 66t
NIDDK (National Institutes of Diabetes and Digestive and Kidney Diseases), 290
NIH (National Institutes of Health), 289
Nitazoxanide, 48t-49t
Noncaseating granulomas, 201-202
Noncholera *Vibrio* diarrhea, 30t-32t
Nonspecific anti-diarrheal therapies, 36-37
Nonsteroidal anti-inflammatory drugs. *See* NSAIDs (nonsteroidal anti-inflammatory drugs).
Normal-risk individuals, 257-263, 258t-261t
Normal transit without defecation disorder, 66, 66t
Norwalk virus, 24t-27t, 27-28
Nothing by mouth orders, 137-138
Nottingham Study, 258, 259t
NSABP C07 (National Surgical Adjuvant Breast and Bowel Project), 278t
NSAIDs (nonsteroidal anti-inflammatory drugs), 24t-25t
Nuclear scanning, 124-126
NuLev, 107
NuLYTELY, 16t
Nutritional supplement-induced diarrhea, 16t
- Obstruction series, 133-134
Octreotide, 47, 56-57
Ofloxacin, 28
Olsalazine, 171
Oltipraz, 249-250
Omega-3 fatty acids, 182-184
Omeprazole, 28
One-step surgical procedure, 141, 143
- Open resections, 137
Opiates, 57
Opium, deionated tincture, 47
Oral bicyclic fatty acids, 78-79
Oral diets, intolerance of, 137
Oral ulcers, 21t
Organizations, societies, and associations, 285-291
Orthostatic dizziness, 55-56
Osmolar laxatives, 73-81, 74t, 77f-78f, 80f. *See also* Laxatives.
Osmotic diarrhea, 15-17, 16t
Osteomalacia, 208
Osteoporosis, 178
OTC (over-the-counter) laxatives, 65, 73-75. *See also* Laxatives.
Overviews and summaries. *See also* *Fundamental concepts*.
of constipation, 63, 82
of CRC, 233, 257-258, 269
epidemiology and biology of, 233
management of, 269
screening techniques for, 257-258
of diarrhea, 23-25, 51-53
acute and in AIDS, 23-25
chronic, 51-53
fundamentals of, 15
of diverticulitis, 131
of diverticulosis, 117-118
of IBD, 145, 155, 199-200
Crohn's disease, 199-200
fundamentals of, 145
UC, 155
of IBS, 85, 91, 99-102, 115
diagnosis of, 91
fundamentals of, 85
management of, 99-102, 115
Oxalate kidney stones, 210
Oxaliplatin, 277
Oxybutynin, 57
- PABA (para-aminobenzoic acid), 61
Painful diverticular disease, 122
Palliative resections, 280
Pancolitis, 268
Pancreatic cholera, 20t-21t
Pancreatic insufficiency, 19t
Pancreatitis, 171, 210
Pantoprazole, 28
Para-aminobenzoic acid. *See* PABA (para-aminobenzoic acid).
Parasites and parasitic infections, 24t-25t, 35t, 51-53
Parenteral nutrition, 151-153
Parkinson's disease, 66, 66t
Pathogenesis, CRC (colorectal cancer), 240-244, 241f, 243f-244f
Pathogens. *See also* *under individual pathogens*.
Aeromonas spp, 24t-25t
Bacillus cereus, 24t-25t
Bacteroides spp and *Bacteroides fragilis*, 138
Blastocystis carinii, 26t-27t
Campylobacter spp and *Campylobacter jejuni*, 21-32, 21t, 24t-27t, 30t-32t, 211

Pathogens (continued)

Candida albicans, 24t-27t
Chlamydia trachomatis, 23-27, 26t-27t
Clostridium spp, 24t-27t, 59-60, 211, 215-216
Clostridium difficile, 24t-27t, 59-60, 211, 215-216
Clostridium perfringens, 24t-25t
Coccidioides, 26t-27t
Cryptococcus, 26t-27t
Cryptosporidium, 21t, 24t-27t
Cyclospora cayetanensis, 24t-27t
Entamoeba histolytica, 23-24, 24t-27t
Escherichia coli, 24t-27t, 30t-32t, 138, 211
Giardia spp and *Giardia lamblia*, 21t, 24t-27t, 54-55
Histoplasma spp, 26t-27t
Isospora belli, 26t-27t
Leishmania donovani, 26t-27t
Listeria monocytogenes, 24t-25t
Mycobacterium spp, 26t-27t, 200, 211
Mycobacterium avium-intracellulare, 26t-27t, 211
Mycobacterium paratuberculosis, 200
Pneumocystis carinii, 183
Pseudomonas aeruginosa, 131, 138
Salmonella spp and *Salmonella enteritidis*, 21t, 24t-27t, 30t-32t, 211
Shigella spp, 21t, 24t-27t, 30t-32t
Staphylococcus aureus, 24t-25t
Vibrio spp, 24t-27t
Yersinia enterocolitica, 21t, 24t-25t, 211
Pathology, Crohn's disease, 200-202, 201f-202f
PDQ (Physician Data Query), 291
Pediatric Crohn's and Colitis Association, 290
PEG (polyethylene glycol)-containing lavage solutions, 16t
Pelvic abscesses, 141
Pelvic floor dysfunction, 66, 66t, 67t, 68-69, 70t
Pelvic osteomyelitis, 208
Pentasa, 174t. *See also* Mesalamine.
Peptic ulcers, perforated, 132
Pepto-Bismol, 27-28. *See also* Bismuth subsalicylate.
Percutaneous gastrostomy, 281
Perforated peptic ulcers, 132
Peridiverticular abscesses, 141
Peritonitis, 132, 138, 141-142
Peritonitis, generalized, 131-132, 141-142
PETACC-3 (Pan European Trial of Adjuvant Colon Cancer)-3, 278t
Pharmacologic agents and therapies. *See also under individual drugs and drug classes.*
4-ABA, 171
5-ASA, 56-57, 170-171, 174t
5-FU, 24t-25t, 276-283, 278t
5-HT, 75-76
6-MP, 58, 180-183, 210
acyclovir, 48t-49t
albendazole, 48t-49t
aloe, 18t
alosetron, 105-107, 106t, 109-113
aminosalicylates, 58, 170-177, 175f
amoxicillin, 136-137

Pharmacologic agents and therapies (continued)

amoxicillin/clavulanate, 136-137
amphotericin, 48t-49t
ampicillin, 138
ampicillin/sulbactam, 138
antacids, 15-17, 16t, 66, 66t
antibiotics, 24t-25t, 27-28, 57, 136-142, 180
anticholinergic antispasmodics, 105-107, 106t
anticonvulsants, 66, 66t
antidepressants, low-dose vs tricyclic, 66, 66t, 73, 105-107, 106t
antihypertensives, 66, 66t
antioxidants, 252-254
antiparkinsonian agents, 66, 66t
antispasmodics, 66, 66t
aspirin, 252-253, 252t-253t
azathioprine, 58, 180-182, 182f, 210
azithromycin, 28, 30t-32t, 48t-49t
azithromycin/ethambutol, 48t-49t
bacitracin, 44t
balsalazide, 58, 171-176, 174t
belladonna alkaloids, 105-107, 106t
betacarotene, 251-254
bevacizumab, 277
bisacodyl, 18t, 74t
bismuth subsalicylate, 27-28
budesonide, 58
calcium channel blockers, 66, 66t
calcium polycarboxophil, 74t, 105-107, 106t
calcium supplements, 249-250, 253t
capecitabine, 278t
carcinogen-blocking agents, 249-250
cascara, 18t, 58-59
celecoxib, 253-254, 253t
cetuximab, 277
chemotherapy, 24t-25t, 249-253, 277-280, 278t
adjuvant, 24t-25t, 277-280, 278t
chemopreventive agents, 249-253
chlordiazepoxide/clindinium bromide, 105-107, 106t
cholestyramine, 44t, 105-107, 106t, 109
ciprofloxacin, 27-28, 30t-32t, 48t-49t, 136-137
clarithromycin, 48t-49t
clindamycin, 41
clinical trials and research studies for. *See* Clinical trials and research studies.
clonidine, 57
codeine, 56-57
colchicine, 24t-25t
CoLYTE, 16t, 128
for constipation, 72-81, 74t, 75-81, 77f-78f, 80f
corticosteroids, 56-57, 178-180, 217
COX-2 inhibitors, 252-253, 253t
for CRC, 269-284
curcumin, 252-254
cyclosporine, 182-183
danthron, 18t
DFMO, 252-253

Pharmacologic agents and therapies (*continued*)

for diarrhea, 51-62
 acute, 26-29, 28-29, 30t-32t, 34-40
 chronic, 51-62
dicyclomine, 105-107, 106t
digoxin, 24t-25t
diphenoxylate-atropine, 47, 56-57, 109
diuretics, 24t-25t, 66, 66t
for diverticulitis, 136-144
docusate sodium, 18t
esomeprazole, 28
famciclovir, 48t-49t
fiber supplements, 73-74
FLOX, 277-284, 278t
fluconazole, 48t-49t
fluoroquinolones, 28, 30t-32t, 56-57
FOLFOX, 277-284, 278t
folic acid supplements, 249-250
FU, 276-283, 278t
fumagillin, 48t-49t
gastrointestinal lavage solutions, 16t
gentamicin, 138
glycerin, 74t
GoLYTELY, 16t, 128
HAART, 45-46, 48t-49t
histamine, receptor antagonists, 24t-25t
hydrocortisone, 179-180
hyoscyamine, 105-107, 106t
imipenem/cilastatin, 138
immunomodulators, 180-185
immunosuppressive agents, 58
indole-3-carbinol, 249-250
infliximab, 184-185
irinotecan, 277
iron supplements, 66, 66t
lactulose, 74t, 105-107, 106t
lansoprazole, 28
laxatives, 15-17, 16t, 24t-25t, 51-61, 71-81, 74t, 77f-78f, 80f
 abuse of, 51-61
 bulk-forming, 73-81, 74t, 77f-78f, 80f
 osmolar, 73-81, 74t, 77f-78f, 80f
 OTC, 65, 73-75
 saline, 75
 stimulant, 18t, 73-81, 74t, 77f-78f, 80f
levamisole, 277
levofloxacin, 28, 30t-32t, 136-138
loperamide, 28, 47, 56-57, 105-109, 106t
lubiprostone, 73, 78-82, 80f
LV, 277-280, 278t
magnesium-containing drugs, 24t-25t, 74t, 105-107, 106t
meperidine, 138
meropenem, 138
mesalamine, 58, 174t, 176-178, 210
methotrexate, 24t-25t, 58
methylcellulose, 74t, 105-107, 106t
metronidazole, 30t-32t, 44t, 56-57, 136-138, 180
morphine, 138

Pharmacologic agents and therapies (*continued*)

narcotics, 66, 66t
nitazoxanide, 48t-49t
NSAIDs, 24t-25t
NuLYTELY, 16t, 128
octreotide, 47, 56-57
ofloxacin, 28
olsalazine, 171, 174t
oltipraz, 249-250
omega-3 fatty acids, 182-184
omeprazole, 28
opiates, 57
opium, deionated tincture, 47
oxaliplatin, 277
oxybutynin, 57
pantoprazole, 28
PEG-containing lavage solutions, 16t
phenobarbital, 105-107, 106t
phenolphthalein, 18t, 73-74
phenothiazines, 66, 66t
piperacillin/tazobactam, 138
prednisolone, 179-180
protease inhibitors, 46-47
proton pump inhibitors, 28
psyllium and psyllium husk, 74t, 105-107, 106t
quinidine, 24t-25t
rabeprazole, 28
ricinoleic acid, 18t
rifabutin, 48t-49t
rifaximin, 27-28
salicylates, 258t
senna, 18t, 58-59, 74t
serotonin receptor antagonists, 66, 66t
sorbitol, 15-17, 16t, 74t, 105-107, 106t
SSRIs, 66, 66t, 105-107, 106t
steroids, 210
sulfasalazine, 58, 170-177, 174t, 210
sulindac, 252-254, 252t
tegaserod, 73-78, 77f-78f, 82, 105-108, 106t
tetracyclines, 56-57
TMP/SMX, 30t-32t, 48t-49t, 56-57, 136-137
for UC, 170-193, 172f-173f, 174t, 175f, 192t
valganciclovir, 48t-49t
vancomycin, 44t
vitamin supplements, 250t-251t, 252-254, 258t
 vitamin A, 250t-251t
 vitamin C, 258t
 vitamin E, 250t-251t, 252-254
 Xeloda, 278t
Phenobarbital, 105-107, 106t
Phenolphthalein, 18t, 73-74
Phenothiazines, 66, 66t
Pheochromocytomas, 20t-21t, 52t-53t
Phlegmons, 131-132
Physical activity levels, 64-65
Physical examinations, 17, 71, 95-98

Physician Data Query. *See* PDQ (Physician Data Query).

PillCam SB, 213-215

Piperacillin/tazobactam, 138

Pneumaturia, 132, 139

Pneumocystis carinii, 183

Polyethylene glycol. *See* PEG (polyethylene glycol)-containing lavage solutions.

Polypectomy, 272-273, 279-280

Polyps, 54-55, 234-240, 236f-240f

Positive family histories, 263-268, 264f-265f

Postural hypotension, 21t

Pouchitis, 180

Prednisolone, 179-180

Premalignant polyps, 234-240

Primary anastomosis, 137, 140

Primary diseases and disorders, 66, 67t

Primary sclerosing cholangitis. *See* PSC (primary sclerosing cholangitis).

Procarcinogens, 249-250

Proctitis, 23-24

Proctocolectomy, 267-268

Proctoscopy, 124, 124f

Prosthetic joints, 30t-32t

Protease inhibitors, 46-47

ProctoFoam-HC, 179-180

Proton pump inhibitors, 28

PSC (primary sclerosing cholangitis), 210

Pseudomonas aeruginosa, 131, 138

Pseudopancreatic cholera syndrome, 52t-53t

Psychological stressor conceptual model, 87-88, 89f

Psychological therapy, 104-105

Psyllium and psyllium husks, 74t, 105-107, 106t

Purinethol, 180-183. *See also* 6-MP (mercaptopurine).

Purulent peritonitis, 141-142

Putative risk factors, 149t

Pylephlebitis, 132

Pyoderma gangrenosum, 21t, 208

Pyrosis, 93

Questran powder, 109. *See also* Cholestyramine.

Quinidine, 24t-25t

Rabeprazole, 28

Radiation enteritis, 52t-53t

Radiotherapy, 276-277

Reanastomoses, coloanal, 276

Rectal prolapse, 63

Rectal sparing, 203

Rectosigmoid polyps, 235, 236f

Rectosigmoid resection, 274-276, 275f

Reference resources. *See also under individual topics.*

for constipation, 83-84

for CRC, 254-255, 268, 284

epidemiology and biology of, 254-255

management of, 284

screening techniques for, 268

for diarrhea, 17

for diverticulitis, 144

Reference resources (*continued*)

for diverticulosis, 129

educational materials, 285-291

for IBD, 153, 197-198, 231

Crohn's disease, 231

fundamentals of, 153

UC, 197-198

for IBS, 88, 98, 116

diagnosis of, 98

fundamentals of, 88

management of, 116

Web sites, 285-291

Remicade, 184-185. *See also* Infliximab.

Research studies. *See* Clinical trials and research studies.

Resource information and educational materials, 285-291.

Retroperitoneal air, 133-134

Ricinoleic acid, 18t

Rifabutin, 48t-49t

Rifaximin, 27-28

Right colonic diverticulitis, 132-133, 133t, 136-138

Risk factors, 149t, 245-249, 245f, 247f, 248t, 257-263, 258t-261t

ROME III criteria, 67-69, 69t, 91-94, 92t

Rotavirus, 24t-25t, 24t-27t, 27-28

Routine changes, 65

Rowasa enemas, 174t. *See also* Mesalamine.

SAGES (Society of American Gastrointestinal and Endoscopic Surgeons), 291

Salicylates, 258t

Saline laxatives, 75

Salmonella spp and *Salmonella enteritidis*, 21t, 24t-27t, 30t-32t, 211

Salpingo-oophorectomy, bilateral, 267-268

Sandostatin, 47

Scanning, nuclear, 124-126

Scleroderma, 19t, 66, 66t

Scopolamine, 107

Screening techniques, 257-268

algorithm for, 264f-265f

APC genetic testing, 267-268

colonoscopy, 260t-261t, 262

CT colonography, 260t-261t, 262-263

DCBEs, 260t-261t, 262

flexible sigmoidoscopy, 260t-261t, 262

FOBTs, 257-261, 258t-261t

normal-risk individuals, 257-263, 258t-261t

overviews and summaries of, 257-258

positive family histories, 263-268, 264f-265f

Secretory diarrhea, 18t-19t

Selective serotonin reuptake inhibitors. *See* SSRIs (selective serotonin reuptake inhibitors).

Self-medication impacts, 65

Senna, 18t, 58-59, 74t

Sequential strategies, 91

Serotonin receptors, 66, 66t, 75-76

Severe-to-fulminant Crohn's disease, 225-226. *See also* Crohn's disease.

Severity classification, 103t

Sexually-transmitted diseases. *See* STDs (sexually-transmitted diseases).

Shigella spp, 21t, 24t-27t, 30t-32t

- Shilling tests, 60-61
- Short-bowel syndrome, 18t
- Sigmoid resection, 274-276, 275f
- Sigmoidectomy, 140
- Sigmoidoscopy, 122
- Sigmoidoscopy, flexible, 54-55, 72, 260t-261t, 262
- Six-MP (mercaptopurine), 58, 180-183, 210
- Skip areas, 203
- Slow transit, 66, 66t
- Slow-transit, 66, 67t, 68-69
- Societies, organizations, and associations, 285-291
- Society for Surgery of Alimentary Tract. *See* SSAT (Society for Surgery of the Alimentary Tract).
- Society of American Gastrointestinal and Endoscopic Surgeons. *See* SAGES (Society of American Gastrointestinal and Endoscopic Surgeons).
- Sorbitol, 15-17, 16t, 74t, 105-107, 106t
- Specific anti-diarrheal therapies, 37-38
- Spinal cord injuries, 66, 66t
- SSAT (Society for Surgery of the Alimentary Tract), 291
- SSRIs (selective serotonin reuptake inhibitors), 66, 66t, 105-107, 106t
- Staging criteria, CRC (colorectal cancer), 269-270, 270f, 271t, 272f-273f
- Staphylococcus aureus*, 24t-25t
- STDs (sexually-transmitted diseases), 23-24
- Steatorrhea, 57, 210
- Stenosis, 202
- Steroids, 210. *See also under individual drug names.*
- Stimulant laxatives, 18t, 73-81, 74t, 77f-78f, 80f. *See also* Laxatives.
- Stressor conceptual model, 87-88, 89f
- Stroke, 66, 66t, 210, 253
- Studies and trials. *See* Clinical trials and research studies.
- Subtotal colectomy, 81-82
- Sucrase-isomaltase deficiency, 15-17, 16t
- Sulbactam. *See* Ampicillin/sulbactam.
- Sulfamethoxazole. *See* TMP/SMX (trimethoprim/sulfamethoxazole).
- Sulfasalazine, 58, 210
- Sulindac, 252-254, 252t
- Superficial carcinomas, 272-273
- Supplement-induced diarrhea, 16t
- Suprapubic catheters, 140
- Sugar-free gum and candy, 16t
- Surgical interventions, 81-82, 142-144, 226-230, 229f, 273-276, 275f
 - for constipation, 81-82
 - for CRC, 273-276, 275f
 - for Crohn's disease, 226-230, 229f
 - for diverticulitis, 142-144
 - for UC, 190-193
- Symax Duotabs, 107. *See also* Hyoscyamine.
- Symptom severity classification, 103t
- Syphilis, 23-24
- Systemic disorders, 66, 66t
- Systemic infections, 139
- Systemic lupus erythematosus, 19t
- Systemic mastocytosis, 21t, 52t-53t
- Tachycardia, 140-142
- Tags, mucosal, 234-235
- Tazobactam. *See* Piperacillin/tazobactam.
- Tegaserod, 73-78, 75-78, 77f-78f, 82, 105-108, 106t
- Tetracyclines, 56-57
- Therapies, pharmacologic. *See* Pharmacologic agents and therapies.
- Thromboembolic complications, 210
- Thyroid function studies, 54-55
- TMP/SMX (trimethoprim/sulfamethoxazole), 30t-32t, 48t-49t, 56-57, 58, 136-137, 174t, 176-178, 210
- TMPT (thiopurine methyltransferase), 181-183
- TNM (tumor-node-metastasis) staging, 269-270, 271t
- Tooth loss, 64
- Total parenteral nutrition. *See* TPN (total parenteral nutrition).
- Toxic megacolon, 190
- Toxicity, clinical, 137
- TPN (total parenteral nutrition), 151-153, 153t, 210
- Transit studies, 70t
- Transvaginal ultrasound, 267-268
- Transverse colectomy, 274-276
- Transverse colon polyps, 235, 236f
- Traveler's diarrhea, 25-28
- Trials, clinical. *See* Clinical trials and research studies.
- Tricyclic antidepressants, 66, 66t, 105-107, 106t
- Trimethoprim/sulfamethoxazole. *See* TMP/SMX (trimethoprim/sulfamethoxazole).
- Tumor-node-metastasis staging. *See* TNM (tumor-node-metastasis) staging.
- Turcot's syndrome, 246
- Two-step Hartmann's procedure, 144
- UC (ulcerative colitis), 155-198. *See also* IBD (inflammatory bowel disease).
 - cancer surveillance recommendations for, 192t, 193-197, 194f-195f
 - clinical severity of, 185-190
 - Colitis, 56-58, 58f
 - diagnosis of, 160-166, 162t-163t, 163f, 166f
 - epidemiology of, 155
 - etiology of, 156
 - extraintestinal manifestations of, 167-169, 168f
 - genetic factors for, 156
 - management of, 170-193
 - overviews and summaries of, xii-xiii, 155
 - pathology of, 156-159, 158f-159f
 - pharmacologic therapies, 170-193, 172f-173f, 174t, 175f, 192t
 - physical findings for, 160
 - surgical interventions for, 190-193
 - symptoms of, 160
- Ulcerative colitis. *See* UC (ulcerative colitis).
- Ulcers, peptic, 132
- Ultrasound, 54-55, 134t-135t, 141
- United States agencies and departments, 73, 109-110, 176-177, 249-250, 289
 - DHHS, 249-250
 - FDA, 73, 109-110, 176-177
 - NIH, 289
 - USDA, 249-250
- Unknown origin, chronic diarrhea of, 60-61
- Unpasteurized milk, 52t-53t
- Uremia, 66, 66t
- Urethral catheters, 140

Urgency, 132
UTIs (urinary tract infections), 139

Vagotomy, 18t, 52t-53t
Valganciclovir, 48t-49t
Vancomycin, 44t
Vascular grafts, 30t-32t
Vibrio spp., 24t-27t
Villoglandular adenomas, 273-274
Villous adenomas, 52t-53t, 273-274
Viral infections, 24t-25t
Virtual colonoscopy, 260t-261t, 262-263
Vitamin supplements, 250t-251t, 252-254, 258t
 vitamin A, 250t-251t
 vitamin C, 258t
 vitamin E, 250t-251t, 252-254

Waterborne diarrhea outbreaks, 29
WDHA (watery diarrhea, hypokalemia, achlorhydria), 19t
Web sites, 285-291
Whipple's disease, 20t-21t, 54-55

X-ACT (Xeloda in Adjuvant Colon Cancer Therapy) trial, 278t
Xeloda, 278t
Xerostomia, 106-107
Xifaxan, 27-28. *See also* Rifaximin.
Xylose, 60-61

Yersinia enterocolitica, 21t, 24t-25t, 211

Zelnorm, 73, 75-78, 108. *See also* Tegaserod.
Zollinger-Ellison syndrome, 19t